Imexpharm Corporation
Imexpharm Corporation, a leading pharmaceutical company based in Vietnam, has been a key player in the industry since its establishment in 2003. With its headquarters in Ho Chi Minh City, the company operates extensively across Southeast Asia, focusing on the development, manufacturing, and distribution of high-quality generic medicines and healthcare products. Imexpharm is renowned for its diverse portfolio, which includes a wide range of pharmaceuticals, from antibiotics to cardiovascular medications. The company prides itself on its commitment to quality and innovation, utilising advanced technology and stringent quality control measures to ensure the efficacy and safety of its products. Recognised for its significant contributions to the healthcare sector, Imexpharm has achieved notable milestones, including various certifications and partnerships that enhance its market position. With a strong emphasis on research and development, Imexpharm continues to expand its reach and impact in the pharmaceutical landscape.
DitchCarbon Score
How does Imexpharm Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Imexpharm Corporation's score of 22 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Imexpharm Corporation's reported carbon emissions
Imexpharm Corporation, headquartered in Vietnam (VN), currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Consequently, the company has not established any documented reduction targets or climate pledges. As of now, Imexpharm Corporation does not inherit emissions data from a parent company, nor does it participate in any recognised climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). This lack of data and commitments places Imexpharm in a position where it may need to enhance its climate strategy to align with industry standards and expectations for corporate sustainability. In summary, without specific emissions data or reduction initiatives, Imexpharm Corporation's current climate commitments remain unclear, highlighting an opportunity for the company to develop a more robust environmental strategy.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Imexpharm Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
